Orphan drug exclusivity gives pharmaceutical companies seven years of market protection for rare-disease treatments, driving development where profits were once impossible. Here's how it works, why it matters, and what's changing.
Orphan drug exclusivity gives pharmaceutical companies seven years of market protection for rare-disease treatments, driving development where profits were once impossible. Here's how it works, why it matters, and what's changing.